Justin W. Yorke - Jan 27, 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Director
Signature: /s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol: PCSA
Transactions as of: Jan 27, 2022
Transactions value $: -$6,118
Form type: 4
Date filed: 1/31/2022, 03:45 PM
Previous filing: Dec 7, 2021
Next filing: Apr 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Sale	-$6.12K	-1.85K	-0.35%	$3.30	533K	Jan 27, 2022	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC	F1
holding	PCSA	Common Stock						9.32K	Jan 27, 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.37, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.37, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.